(-0.07%) 5 474.75 points
(-0.10%) 38 781 points
(-0.04%) 19 914 points
(0.21%) $80.50
(1.40%) $2.83
(0.22%) $2 334.10
(-0.19%) $29.34
(-0.23%) $968.70
(0.02%) $0.932
(-0.15%) $10.64
(0.07%) $0.788
(-1.86%) $86.81
Live Chart Being Loaded With Signals
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada...
Stats | |
---|---|
Šios dienos apimtis | 380 142 |
Vidutinė apimtis | 338 357 |
Rinkos kapitalizacija | 2.76B |
EPS | $-0.620 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $0 ) 2024-08-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-13.46 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0540 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-05 | Patou Gary | Buy | 15 542 | Stock Option (Right to Buy) |
2024-06-05 | Machado Patrick | Buy | 15 542 | Stock Option (Right to Buy) |
2024-06-05 | Gover Justin D. | Buy | 15 542 | Stock Option (Right to Buy) |
2024-06-05 | Garofalo Elizabeth A. | Buy | 15 542 | Stock Option (Right to Buy) |
2024-06-05 | Gannon Steven | Buy | 15 542 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
65.45 |
Last 100 transactions |
Buy: 2 285 491 | Sell: 531 159 |
Tūris Koreliacija
Xenon Pharmaceuticals Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ZS | 0.893 |
IRWD | 0.887 |
DMRC | 0.873 |
TNGX | 0.872 |
WRAP | 0.868 |
TACT | 0.862 |
TBBK | 0.862 |
MDB | 0.861 |
ASUR | 0.86 |
NEPH | 0.858 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
TIGO | -0.885 |
IGLD | -0.877 |
GLDI | -0.865 |
MRVI | -0.845 |
BZFD | -0.844 |
PPC | -0.843 |
SLVO | -0.843 |
KNTK | -0.842 |
SANG | -0.841 |
KALU | -0.84 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Xenon Pharmaceuticals Inc Koreliacija - Valiuta/Žaliavos
Xenon Pharmaceuticals Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-3.54M (0.00 %) |
EPS: | $-2.73 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-3.54M (0.00 %) |
EPS: | $-2.73 |
FY | 2022 |
Pajamos: | $9.43M |
Bruto pelnas: | $-96.33M (-1 021.13 %) |
EPS: | $-2.07 |
FY | 2021 |
Pajamos: | $18.44M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.770 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.